

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.  
This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Esaxerenone

December 17, 2024

### **Therapeutic category**

Antihypertensives

### **Non-proprietary name**

Esaxerenone

### **Safety measure**

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision												
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Potassium-sparing diuretics (spironolactone, triamterene, potassium canrenoate), aldosterone antagonists (eplerenone), potassium preparations (potassium chloride, potassium gluconate, potassium aspartate, potassium iodide, potassium acetate)</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table><tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr><tr><td>Potassium preparations Potassium chloride Potassium gluconate Potassium aspartate Potassium iodide Potassium acetate</td><td>Serum potassium levels may increase.</td><td>Potassium retention effect may be enhanced.</td></tr></table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Potassium preparations Potassium chloride Potassium gluconate Potassium aspartate Potassium iodide Potassium acetate	Serum potassium levels may increase.	Potassium retention effect may be enhanced.	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Potassium-sparing diuretics (spironolactone, triamterene, potassium canrenoate), aldosterone antagonists (eplerenone), potassium preparations (potassium chloride, potassium gluconate, potassium aspartate, potassium iodide <u>(excluding the cases where potassium iodide is used for prevention/reduction of internal exposure of the thyroid gland to radioactive iodide)</u>, potassium acetate)</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table><tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr><tr><td>Potassium preparations Potassium chloride Potassium gluconate Potassium aspartate Potassium iodide <u>(excluding the cases where potassium iodide is used for prevention/reduction of internal exposure of the thyroid gland to radioactive iodide)</u> Potassium acetate</td><td>Serum potassium levels may increase.</td><td>Potassium retention effect may be enhanced.</td></tr></table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Potassium preparations Potassium chloride Potassium gluconate Potassium aspartate Potassium iodide <u>(excluding the cases where potassium iodide is used for prevention/reduction of internal exposure of the thyroid gland to radioactive iodide)</u> Potassium acetate	Serum potassium levels may increase.	Potassium retention effect may be enhanced.
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors											
Potassium preparations Potassium chloride Potassium gluconate Potassium aspartate Potassium iodide Potassium acetate	Serum potassium levels may increase.	Potassium retention effect may be enhanced.											
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors											
Potassium preparations Potassium chloride Potassium gluconate Potassium aspartate Potassium iodide <u>(excluding the cases where potassium iodide is used for prevention/reduction of internal exposure of the thyroid gland to radioactive iodide)</u> Potassium acetate	Serum potassium levels may increase.	Potassium retention effect may be enhanced.											

10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)

Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Angiotensin-converting enzyme inhibitors Imidapril hydrochloride Enalapril maleate, etc. Angiotensin II receptor blockers Olmesartan medoxomil Azilsartan Telmisartan, etc. Aliskiren fumarate Ciclosporin Tacrolimus Drospirenone combination drugs	Serum potassium levels may increase. Careful attention should be paid such as measuring serum potassium levels more frequently.	Potassium retention effect may be enhanced.

10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)

Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Angiotensin-converting enzyme inhibitors Imidapril hydrochloride Enalapril maleate, etc. Angiotensin II receptor blockers Olmesartan medoxomil Azilsartan Telmisartan, etc. Aliskiren fumarate Ciclosporin Tacrolimus Drospirenone combination drugs <u>Potassium iodide (cases when potassium iodide is used for prevention/reduction of internal exposure of the thyroid gland to radioactive iodide)</u>	Serum potassium levels may increase. Careful attention should be paid such as measuring serum potassium levels more frequently.	Potassium retention effect may be enhanced.